Genome sequencing business Ultima Genomics has arrive out of stealth and declared $600 million in funding. Established in 2016 by its Israeli CEO Gilad Almogy, the business has 350 workers like 50 in Israel at improvement facilities in Rehovot and Hod Hasharon, and remarkably has managed to protect against any leaks of details from its workforce, buyers and enhancement facilities.

The business has now disclosed that it has produced a sequencing equipment, which it statements, backed up by investigation established to be released in major scientific periodicals, permits genome sequencing for $100, in contrast with the $500-600 it fees applying its rival Illumina (Nasdaq: ILMN). In addition, Ultima Genomics statements that its genomic sequencing is faster and further – in other phrases, it gives far more facts about the genome, far more swiftly.

The positive aspects of these advancements, which are authorized as a result of patents that the corporation has not yet discovered, are primarily in two instructions. Through this technological innovation, the enterprise estimates and hopes, it will be achievable to realize genome sequencing even down to solitary cells, and so diagnose diseases even earlier than at current, mostly most cancers. In addition, sequencing that is cheaper, more quickly and richer in details, will allow much faster development in initiatives that compare the genetics of the actual morbidity of substantial figures of persons, in buy to map the genes concerned in a variety of disorders.

Resources at Ultima Genomics say that the rationale for the secrecy above the several years was the wish to arrive at the position where the corporation could prove its product or service, just before creating any announcements. The corporation also chosen not to stir up its rivals, mainly Illumina.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and leadership system. Almogy is currently resident in the US. He was a senior vice president at Utilized Materials in advance of founding photo voltaic energy firm Cogenra Solar in 2009, which was obtained by SunPower in 2015. In late 2016, Almogy established Ultima.

Almogy said, “DNA is nature’s storage media and the instruction set for every residing organism, yet with present systems, we are not able to obtain that facts at the scale desired to definitely fully grasp sophisticated biology. Our architecture is intended for radical scaling, and the $100 genome is just the initially case in point of what it can produce. We are dedicated to continually generate down the cost of genomic information until it is routinely used in every element of the health care system.”




Related Articles




aMoon closes $660m Israeli overall health-tech VC fund







Ultima Genomics CSO Doron Lipson added, “Experts and clinicians constantly make tradeoffs among the breadth, depth, and frequency of genomic facts they collect. By beating the constraints of regular next-era sequencing systems, scientists can now design and style experiments and scientific assays that were earlier impossible.”

One particular of the initially buyers in Ultima Genomics was Israeli billionaire and Test Place founder Marius Nacht, who is also a graduate of the IDF’s Talpiot software. Nqcht founded the aMoon healthtech and existence science expense fund, to begin with investing his individual belongings in advance of becoming an impartial fund, which in the latest a long time elevated a $750 million growth fund. aMoon has also invested in Ultima Genomics.

Other buyers in Ultima Genomics include things like D1 Cash, Andreessen Horowitz, Basic Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.

Complete disclosure: Marius Nacht is the previous everyday living husband or wife of Anat Agmon, portion of the controlling shareholders in “Globes.” They are involved in a personal and financial dispute

Posted by Globes, Israel organization news – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.